

Press release

IMA: agreement signed for the acquisition of a minority equity interest of CONTINUUS Pharmaceuticals

IMA S.p.A. acquired a minority equity interest of **CONTINUUS Pharmaceuticals** through a Series A financing round of \$2 million which increased the total capital raised by CONTINUUS Pharmaceuticals to over \$2.4 million. CONTINUUS Pharmaceuticals is commercializing a novel **Integrated Continuous Manufacturing** (**ICM**) process to deliver high-quality and affordable medications to patient faster. The vision of CONTINUUS Pharmaceuticals is to transform how small-molecule drugs are developed, manufactured, and delivered to patients. This includes establishing Centers of Excellence in Pharmaceutical Manufacturing throughout the United States.

IMA is a global leader in the manufacturing of pharmaceutical equipment and will contribute its expertise towards the commercialization of CONTINUUS's novel manufacturing process and supporting the development of novel equipment. Previous seed investors also participated in this round. This transaction triggered the execution of an exclusive license for several novel continuous manufacturing technologies developed at MIT (Massachusetts Institute of Technology). With this financing the company is now looking to launch its Central Development Facility in Massachusetts.

For further information, please visit the website: **www.continuuspharma.com**

Established in 1961, IMA is world leader in the design and manufacture of automatic machines for the processing and packaging of pharmaceuticals, cosmetics, tea, coffee and food. The Group has more than 3,600 employees, more than 1,600 of whom overseas, and can count on 25 production plants in Italy, Switzerland, the United Kingdom, the United States, India and China. IMA has an extensive sales network comprising 27 branches which provide sales and service in Italy, France, Switzerland, the United Kingdom, Germany, Austria, Spain, Poland, Israel, Russia, the United States, India, China, Malaysia, Thailand and Brazil, representative offices in Central and East European countries and over 50 agencies covering a total of more than 70 countries. IMA is also participating in one joint-venture in China for production and service. IMA S.p.A. has been listed on the Milan Stock Exchange since 1995 and in 2001 joined the STAR segment. The following manufacturing companies are part of the IMA Group: Co.ma.di.s. S.p.A., Corazza S.p.A., Delta Systems & Automation Inc., Gima S.p.A., Gima TT S.r.l., Ilapak International SA, Ilapak Italia S.p.A., Ilapak (Langfang) Packaging Machinery Co. Ltd., IMA Industries S.r.l., IMA Life North America Inc., IMA Life (Beijing) Pharmaceutical Systems Co. Ltd., IMA North America Inc., IMA-PG India Pvt. Ltd., PharmaSiena Service S.r.l., Shanghai Tianyan Pharmaceutical Machinery Co. Ltd., Swiftpack Automation Ltd.

For further information:

Andrea Baldani - Investor Relator - tel. +39 051 783111 - e-mail: baldania@ima.it
Maria Antonia Mantovani - Press Office - tel. +39 051 783283 - e-mail: antonia.mantovani@ima.it
www.ima.it (Investor Relations section)